Jaffuel D, Nogue E, Berdague P, et al. - This study was undertaken to investigate if sacubitril–valsartan (SV), a cornerstone of heart failure and reduced ejection fraction (HFrEF) medical treatment, impacts SA is unknown and requires evaluation. Researchers designed a six-centre, prospective, open-label real-life cohort study assessing ambulatory patients eligible for SV (i.e. HFrEF adults who remain symptomatic despite optimal treatment) before and after 3 months of SV (including nocturnal ventilatory polygraphy); 118 patients were final analysed [median age was 66 years, 81.4% male, 36.5% New York Heart Association III–IV, N-terminal pro-B-type natriuretic peptide level of 1564 (701–3376) ng/L, left ventricular ejection fraction of 30 (25–34)%, 60.7% ischaemic HFrEF, 97.5% initially treated with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, 83.9% with beta-blockers, 64.4% with mineralocorticoid receptor antagonists, and 74.6% with diuretics]. The data showed that SV treatment for 3 months in SA patients is associated with a significant decrease in AHI in this real-life population. These outcomes suggest the current guidelines that recommend first an optimization of the HFrEF treatment in patients with HFrEF and central SA. A potential positive airway pressure sparing effect merits future evaluation.